AVBPArriVent BioPharma, Inc.vs its industry peers
A metric-by-metric comparison of ArriVent BioPharma, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVBP본 종목 | $1.4B#7 | — | 3.7x#8 | — | — | -106.6%#10 | — | -45.3%#11 | — | — | 52.3%#7 | — |
| INVA | $1.5B#1 | 4.9x#3 | 1.2x#2 | 3.7x#3 | 14.7%#4 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#2 | — | — |
| DMRA | $1.5B#2 | 3.2x#2 | 2.9x#5 | — | — | -878.8%#12 | — | -40.7%#10 | — | — | 751.8%#2 | — |
| BCAX | $1.5B#3 | — | 3.1x#6 | — | — | -102.9%#9 | — | -29.4%#7 | — | — | 95.6%#6 | — |
| XERS | $1.4B#4 | — | — | 4.9x#5 | 43.7%#1 | 101.0%#2 | 8.5%#3 | — | 20.6%#1 | — | 4.4%#9 | — |
| TRAX | $1.4B#5 | — | 8.3x#11 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LBRX | $1.4B#6 | 1.9x#1 | 4.1x#9 | — | — | 60.1%#5 | — | -7.6%#5 | — | — | 170.5%#5 | — |
| ORIC | $1.3B#8 | — | 3.4x#7 | — | — | -1.3%#7 | — | -34.0%#9 | -40.4%#5 | — | 15.1%#8 | — |
| HROW | $1.3B#9 | — | 84.4x#12 | 4.7x#4 | 36.4%#2 | 70.6%#4 | 11.2%#2 | -33.8%#8 | 13.2%#3 | 6#1 | — | — |
| RARE | $1.3B#10 | — | — | 1.9x#1 | 20.2%#3 | -1.1%#6 | -79.5%#5 | — | — | — | -56.3%#10 | — |
| OMER | $1.3B#11 | 10.0x#4 | — | 17.0x#6 | -34.0%#6 | 97.9%#3 | -166.4%#6 | — | -151.8%#6 | — | 328.7%#4 | — |
| AKTS | $1.2B#12 | — | 2.5x#3 | — | — | — | — | 0.0%#2 | — | — | 23319.4%#1 | — |
| OPK | $1.2B#13 | — | 1.0x#1 | 2.0x#2 | -14.9%#5 | -324.0%#11 | -19.3%#4 | -19058.1%#12 | -13.3%#4 | 4#3 | — | — |
| SPTX | $1.2B#14 | — | 2.8x#4 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ANRO | $1.2B#15 | — | 5.4x#10 | — | — | -2.9%#8 | — | -28.8%#6 | — | — | 664.8%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice